Patents Assigned to The Trustees of the University of Pennsylvania
  • Publication number: 20220081714
    Abstract: Provided herein are systems and methods for using DNA polymerases to record information onto DNA for single cell high time-resolution recording and for high density data storage. The technology provides a DNA polymerase-based nano scale device that can be genetically encoded to record temporal information about the polymerase's environment into an extending single stand of DNA.
    Type: Application
    Filed: January 6, 2020
    Publication date: March 17, 2022
    Applicants: Northwestern University, The Trustees of the University of Pennsylvania, The Trustees of Columbia University in the City of New York
    Inventors: Keith E.J. Tyo, Namita Bhan, Konrad Kording, Joshua Glaser, Johathan Strutz, Alec Castinado
  • Patent number: 11273219
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CART cell in the patient.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: March 15, 2022
    Assignees: The Trustees of the University of Pennsylvania, The Children's Hospital of Philadelphia
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • Patent number: 11273227
    Abstract: Engineered MREG proteins are described. Further described are viral vectors expressing native or engineered MREG proteins. Further described are compositions containing these vectors or proteins formulated for delivery to the eye. Also provided are methods for delivering these native and engineered MREG proteins to ocular cells for treatment of Stargardt's disease, macular degeneration and other ocular disorders.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 15, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Kathleen Boesze-Battaglia
  • Patent number: 11274298
    Abstract: The present invention relates to compositions and methods for generating RNA Chimeric Antigen Receptor (CAR) transfected T cells. The RNA-engineered T cells can be used in adoptive therapy to treat cancer.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 15, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao
  • Patent number: 11274146
    Abstract: This invention relates to inhibition of the complement signaling using an anti-C5a antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5a antibody.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 15, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wenchao Song, Sayaka Sato, Takashi Miwa, Damodar Gullipalli
  • Patent number: 11260358
    Abstract: In one aspects of the invention, a microcapsule includes a film encapsulating a material. The film is formed by complexation of at least two mutually attractive components initially present in an aqueous dispersion comprising a continuous phase and a dispersed phase. The at least one first component is initially present in the continuous phase and the at least one second component is initially present in the dispersed phase. According to another aspect of the invention, provided is a process for forming microcapsules including the step of injecting a dispersed phase having at least a first component into a continuous phase having at least a second component, where the first component and the second component are mutually attractive, such that a film is formed by complexation of the first charged component and the second charged component.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: March 1, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daeyeon Lee, Kathleen J. Stebe, Sarah D. Hann
  • Patent number: 11260642
    Abstract: Disclosed herein are embodiments of methods that utilize dry adhesion tuning of a composite structure to adhere substrates. In some embodiments, the disclosed methods utilize dry adhesion between a composite structure and a substrate and further dynamically control the resulting dry adhesion strength through a heating step, which facilitates rigidity tuning of a core component of the composite structure and/or facilitates thermal control of the interface between the substrate and the composite structure. Also disclosed herein are array devices and other products comprising the disclosed composite structures.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: March 1, 2022
    Assignees: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno, The Trustees of the University of Pennsylvania
    Inventors: Wanliang Shan, Kevin Turner
  • Patent number: 11260139
    Abstract: A device for rapidly sanitizing a surface is described. The device has an enclosure having an opening adapted to insert a surface, and an interior; a liquid nitric oxide solution applicator; and an absorbent material. The liquid nitric oxide solution applicator is in fluid communication with the interior of the enclosure and is adapted to apply liquid nitric oxide solution onto the surface when the surface is positioned within the enclosure. A method of rapidly sanitizing a surface is described. The devices and methods provided herein may be implemented to sanitize the surface of any body part or item that may be placed within the device. An infectious agent on the surface may be killed; i.e., the surface is disinfected. Non-limiting applications of the devices and methods include preventing nosocomial infections or food contamination, sanitizing household items, and implementing sanitizing procedures to comply with FDA Good Manufacturing Practices.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: March 1, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Paul H. Axelsen
  • Publication number: 20220054494
    Abstract: Methods of treating bladder or urethra dysfunction or disease in a subject and methods of increasing bladder smooth muscle contractility or increasing bladder wall volume in a subject are disclosed. In some examples, a purine nucleoside phosphorylase (PNPase) inhibitor or purine nucleoside substrate is administered, such as 8-aminoguanine or forodesine.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 24, 2022
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Vanderbilt University, The Trustees of The University of Pennsylvania
    Inventors: Edwin Kerry Jackson, Lori Ann Birder, Amanda Sue Wolf-Johnston, Roger Dmochowski, Alan J. Wein
  • Patent number: 11253616
    Abstract: The present invention includes an engineered cell comprising a chimeric antigen receptor (CAR) further comprising a nucleic acid molecule comprising a suicide gene comprising a ligand binding domain and a suicide domain wherein the ligand binding domain is capable of binding to radiolabeled tracer or a small molecule suicide switch. This invention also includes methods for inducing apoptosis of an engineered cell, methods for assessing the efficacy or toxicity of an adoptive cell therapy in a subject, methods for detecting the quantity of engineered T cells in a subject, methods for monitoring an immunotherapy treatment in a subject and methods of imaging engineered T cells in a subject. In some embodiments, the imaging is performed via Positron Emission Topography (PET). This invention further includes a chemical inducer of dimerization (CID), wherein the CID is a Bis-Trimethoprim (Bis-TMP).
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: February 22, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Michael Farwell, Mark Sellmyer, Katheryn M. Lohith
  • Patent number: 11253612
    Abstract: A suspension useful for AAV9-mediated intrathecal and/or systemic delivery of an expression cassette containing a hIDS gene is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: February 22, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christian Hinderer, James M. Wilson
  • Publication number: 20220047532
    Abstract: Antagonists that are specific for calcium permeable AMPA subtype glutamate receptors (CP-AMPARs) which lack the GluA2 subunit and methods utilizing the specific AMPA receptor antagonists to treat disorders and diseases having enhanced CP-AMPAR function or expression.
    Type: Application
    Filed: December 3, 2019
    Publication date: February 17, 2022
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Frances JENSEN
  • Patent number: 11247971
    Abstract: Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: February 15, 2022
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE UAB RESEARCH FOUNDATION, VANDERBILT UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • Patent number: 11248199
    Abstract: The presently disclosed subject matter provides a microfluidic device that can simulate capillary blood flow on a fetal side of the device and pooled blood on a maternal side of the device (i.e., intervillous space). The microfluidic device can reconstitute the maternal-fetal interface, can expand the capabilities of cell culture models, and can provide an alternative to current maternal-fetal transfer models.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 15, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Dongeun Huh, Cassidy Blundell
  • Patent number: 11246819
    Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with a composition comprising an effective amount of antimicrobial peptide biofilm enzyme combinations, preferably in the form of a fusion protein. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides a composition for use in the treatment or prevention of a biofilm in a subject, particularly in the oral cavity.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: February 15, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Hyun Koo, Henry Daniell
  • Patent number: 11241506
    Abstract: The invention provides a polynucleotide sequence (e.g., a gene, e.g., DNA or RNA) encoding UGT1A1 (e.g., expressing human UGT1A1). The invention further provides a vector, such as an adeno-associated virus (AAV) vector (e.g., AAV8) having a vector genome including inverted terminal repeat sequences and a UGT1A1 coding sequence operably linked to one or more expression control sequences (e.g., expression control sequences including a liver-specific promoter). Also provided are compositions containing these AAV vectors and methods of treating Crigler-Nijjar syndrome type I, Crigler-Nijjar syndrome type II, and Gilbert syndrome.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: February 8, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Anna P. Tretiakova, Jenny Agnes Sidrane, James M. Wilson
  • Patent number: 11241487
    Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: February 8, 2022
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Henry Daniell, Qiuhong Li, Mohan K. Raizada
  • Patent number: 11241496
    Abstract: Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 8, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David Weiner, Matthew P. Morrow, Jian Yan
  • Patent number: 11241490
    Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 8, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Drew Weissman, Norbert Pardi, Michael Hogan
  • Patent number: 11236177
    Abstract: The invention relates to proximity-based sortase-mediated protein purification and ligation. Specifically, the invention relates to techniques that links protein expression/purification with conjugation to therapeutic agents, imaging agents, or linkers.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 1, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Andrew Tsourkas, Burcin Altun, Hejia Henry Wang, Feifan Yu